Limits...
Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.

Li S, Wu Z, Li L, Liu X - Med. Sci. Monit. (2016)

Bottom Line: RESULTS Compared with before treatment, IL-6 receptor antagonist TCZ significantly improved patients' condition, including DAS28 score, CRP, RF, and CCP levels (P<0.01).Furthermore, TCZ obviously upregulated CD4 naïve T cells proportion and decreased CD4 memory T cells ratio (P<0.01).TCZ also markedly reduced the proportion of Th17 cells and increased the proportion of Treg cells (P<0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatism, Tianjin People's Hospital of Nankai University, Tianjin, China (mainland).

ABSTRACT
BACKGROUND The aim of this study was to investigate the protective effect of interleukin-6 (IL-6) receptor antagonist tocilizumab (TCZ) on rheumatoid arthritis (RA) and its related mechanism. MATERIAL AND METHODS Thirty RA patients receiving long-term methotrexate therapy at moderate and severe active stages were selected and treated with TCZ 8 mg/kg/time iv gtt intravenously guttae every 4 weeks. Peripheral blood was extracted before and 24 weeks after TCZ treatment. Peripheral blood mononuclear cells (PBMC) were collected by density gradient centrifugation. Flow cytometry was used to detect the ratio of CD4 naïve T cells and CD4 memory T cells, Th17 cells, and Treg cells in PBMC. DAS28 score, CRP, RF, and CCP levels in patients were evaluated. RESULTS Compared with before treatment, IL-6 receptor antagonist TCZ significantly improved patients' condition, including DAS28 score, CRP, RF, and CCP levels (P<0.01). Furthermore, TCZ obviously upregulated CD4 naïve T cells proportion and decreased CD4 memory T cells ratio (P<0.01). TCZ also markedly reduced the proportion of Th17 cells and increased the proportion of Treg cells (P<0.01). CONCLUSIONS TCZ can treat RA patients through regulating the ratio of CD4 naïve T cells, CD4 memory T cells, Th17 cells, and Treg cells in PBMC.

No MeSH data available.


Related in: MedlinePlus

TCZ treatment impact on patient condition comparison. ** P<0.01 (** compared with before treatment).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4920098&req=5

f1-medscimonit-22-2113: TCZ treatment impact on patient condition comparison. ** P<0.01 (** compared with before treatment).

Mentions: As shown in Figure 1, DAS28 score, CRP, RF, and CCP levels before treatment were 4.84±1.23, 42.80±22.09 mg/L, 319.98±172.63 U/ml, and 738.25±437.41 U/ml, respectively. After TCZ treatment, DAS28 score, CRP, RF, and CCP levels were 2.61±0.63, 1.63±0.94 mg/L, 154.40±100.64 U/ml, and 135.85±67.85 U/ml, respectively. Compared with before treatment, TCZ treatment significantly decreased DAS28 score, CRP, RF, and CCP levels (P<0.01).


Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.

Li S, Wu Z, Li L, Liu X - Med. Sci. Monit. (2016)

TCZ treatment impact on patient condition comparison. ** P<0.01 (** compared with before treatment).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4920098&req=5

f1-medscimonit-22-2113: TCZ treatment impact on patient condition comparison. ** P<0.01 (** compared with before treatment).
Mentions: As shown in Figure 1, DAS28 score, CRP, RF, and CCP levels before treatment were 4.84±1.23, 42.80±22.09 mg/L, 319.98±172.63 U/ml, and 738.25±437.41 U/ml, respectively. After TCZ treatment, DAS28 score, CRP, RF, and CCP levels were 2.61±0.63, 1.63±0.94 mg/L, 154.40±100.64 U/ml, and 135.85±67.85 U/ml, respectively. Compared with before treatment, TCZ treatment significantly decreased DAS28 score, CRP, RF, and CCP levels (P<0.01).

Bottom Line: RESULTS Compared with before treatment, IL-6 receptor antagonist TCZ significantly improved patients' condition, including DAS28 score, CRP, RF, and CCP levels (P<0.01).Furthermore, TCZ obviously upregulated CD4 naïve T cells proportion and decreased CD4 memory T cells ratio (P<0.01).TCZ also markedly reduced the proportion of Th17 cells and increased the proportion of Treg cells (P<0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatism, Tianjin People's Hospital of Nankai University, Tianjin, China (mainland).

ABSTRACT
BACKGROUND The aim of this study was to investigate the protective effect of interleukin-6 (IL-6) receptor antagonist tocilizumab (TCZ) on rheumatoid arthritis (RA) and its related mechanism. MATERIAL AND METHODS Thirty RA patients receiving long-term methotrexate therapy at moderate and severe active stages were selected and treated with TCZ 8 mg/kg/time iv gtt intravenously guttae every 4 weeks. Peripheral blood was extracted before and 24 weeks after TCZ treatment. Peripheral blood mononuclear cells (PBMC) were collected by density gradient centrifugation. Flow cytometry was used to detect the ratio of CD4 naïve T cells and CD4 memory T cells, Th17 cells, and Treg cells in PBMC. DAS28 score, CRP, RF, and CCP levels in patients were evaluated. RESULTS Compared with before treatment, IL-6 receptor antagonist TCZ significantly improved patients' condition, including DAS28 score, CRP, RF, and CCP levels (P<0.01). Furthermore, TCZ obviously upregulated CD4 naïve T cells proportion and decreased CD4 memory T cells ratio (P<0.01). TCZ also markedly reduced the proportion of Th17 cells and increased the proportion of Treg cells (P<0.01). CONCLUSIONS TCZ can treat RA patients through regulating the ratio of CD4 naïve T cells, CD4 memory T cells, Th17 cells, and Treg cells in PBMC.

No MeSH data available.


Related in: MedlinePlus